Bleakley Financial Group LLC Sells 4,155 Shares of Ionis Pharmaceuticals, Inc. $IONS

Bleakley Financial Group LLC lessened its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 18.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 18,129 shares of the company’s stock after selling 4,155 shares during the period. Bleakley Financial Group LLC’s holdings in Ionis Pharmaceuticals were worth $716,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. CWM LLC boosted its holdings in shares of Ionis Pharmaceuticals by 18.7% during the 1st quarter. CWM LLC now owns 2,435 shares of the company’s stock valued at $73,000 after acquiring an additional 384 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Ionis Pharmaceuticals by 45.6% during the first quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock valued at $42,000 after purchasing an additional 433 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Ionis Pharmaceuticals by 8.5% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,135 shares of the company’s stock worth $185,000 after acquiring an additional 481 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Ionis Pharmaceuticals by 3.5% in the first quarter. Victory Capital Management Inc. now owns 18,641 shares of the company’s stock worth $562,000 after purchasing an additional 637 shares during the last quarter. Finally, GF Fund Management CO. LTD. increased its stake in shares of Ionis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 4,042 shares of the company’s stock valued at $122,000 after buying an additional 727 shares during the period. 93.86% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $70.86 on Friday. The company has a market capitalization of $11.29 billion, a P/E ratio of -38.51 and a beta of 0.33. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $74.42. The business has a 50-day simple moving average of $60.93 and a two-hundred day simple moving average of $44.94.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.19 by $0.51. The firm had revenue of $452.00 million during the quarter, compared to the consensus estimate of $270.90 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The company’s quarterly revenue was up 100.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.45) earnings per share. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IONS has been the topic of several recent analyst reports. Needham & Company LLC boosted their target price on shares of Ionis Pharmaceuticals from $70.00 to $78.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Oppenheimer lifted their target price on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. BMO Capital Markets raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $40.00 to $70.00 in a research note on Wednesday, September 3rd. The Goldman Sachs Group raised shares of Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $45.00 to $65.00 in a research report on Friday, September 26th. Finally, Morgan Stanley boosted their target price on shares of Ionis Pharmaceuticals from $86.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.50.

Insider Activity

In other news, EVP Patrick R. O’neil sold 76,850 shares of the company’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $60.97, for a total value of $4,685,544.50. Following the completion of the sale, the executive vice president owned 5,655 shares in the company, valued at $344,785.35. This represents a 93.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Richard S. Geary sold 57,900 shares of the firm’s stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $65.24, for a total transaction of $3,777,396.00. Following the transaction, the executive vice president directly owned 79,657 shares in the company, valued at $5,196,822.68. The trade was a 42.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 790,202 shares of company stock worth $48,538,661. Company insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.